Basic Information
Comtess
Regulatory Information
EMEA/H/C/000170
September 16, 1998
May 27, 1998
29
September 18, 2024
Company Information
Finland
Orionintie 1 FI-02200 Espoo
ORION CORPORATION
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).